Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has
launched PRAMIPEXOLE dihydrochloride extended-release tablets 0.375 mg,
0.75 mg, 1.5 mg, 3 mg and 4.5 mg, a therapeutic equivalent generic
version of MIRAPEX ER® (pramipexole dihydrochloride)
Extended-Release Tablets in the US market on August 11, 2015, following
the approval by the United States Food & Drug Administration (USFDA).
The MIRAPEX ER® brand and generic had U.S. sales of
approximately $48.3 Million MAT for the most recent twelve months ending
in June 2015 according to IMS Health*.
Dr. Reddy’s PRAMIPEXOLE dihydrochloride extended-release tablets mg are
available in 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg in bottle count
sizes of 30.
MIRAPEX ER is a registered trademark of Boehringer Ingelheim
Pharma GmbH & Co. KG CORPORATION FED REP GERMANY
*IMS National
Sales Perspectives: Retail and Non-Retail MAT June 2015
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is
an integrated pharmaceutical company, committed to providing affordable
and innovative medicines for healthier lives. Through its three
businesses - Pharmaceutical Services & Active Ingredients, Global
Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of
products and services including APIs, custom pharmaceutical services,
generics, biosimilars and differentiated formulations. Our major
therapeutic areas of focus are gastro-intestinal, cardiovascular,
diabetology, oncology, pain management and anti-infectives. Dr. Reddy’s
operates in markets across the globe. Our major markets include – USA,
Russia & CIS, Venezuela and India. For more information, log on to: www.drreddys.com
Disclaimer: This press release may include statements of future
expectations and other forward-looking statements that are based on the
management’s current views and assumptions and involve known or unknown
risks and uncertainties that could cause actual results, performance or
events to differ materially from those expressed or implied in such
statements. In addition to statements which are forward-looking by
reason of context, the words "may", "will", "should", "expects",
"plans", "intends", "anticipates", "believes", "estimates", "predicts",
"potential", or "continue" and similar expressions identify
forward-looking statements. Actual results, performance or events may
differ materially from those in such statements due to without
limitation, (i) general economic conditions such as performance of
financial markets, credit defaults, currency exchange rates, interest
rates, persistency levels and frequency / severity of insured loss
events, (ii) mortality and morbidity levels and trends, (iii) changing
levels of competition and general competitive factors, (iv) changes in
laws and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganisation, including
related integration issues.
The company assumes no obligation to update any information contained
herein.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150812005749/en/
Copyright Business Wire 2015